Wasatch Advisors LP Acquires 36,708 Shares of Dyne Therapeutics, Inc. $DYN

Wasatch Advisors LP increased its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 9.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 443,668 shares of the company’s stock after purchasing an additional 36,708 shares during the period. Wasatch Advisors LP owned 0.27% of Dyne Therapeutics worth $8,044,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC purchased a new stake in Dyne Therapeutics during the 1st quarter valued at approximately $26,000. Strs Ohio bought a new stake in shares of Dyne Therapeutics during the fourth quarter valued at approximately $51,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Dyne Therapeutics in the fourth quarter worth $84,000. Steward Partners Investment Advisory LLC lifted its holdings in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Dyne Therapeutics by 275.1% during the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after acquiring an additional 7,697 shares during the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a report on Friday, May 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Sanford C. Bernstein raised their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Finally, Chardan Capital reiterated a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $34.17.

Dyne Therapeutics Trading Up 1.6%

Shares of DYN opened at $20.94 on Friday. The company’s fifty day moving average is $18.45 and its 200 day moving average is $18.11. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The stock has a market capitalization of $3.46 billion, a PE ratio of -6.50 and a beta of 1.09. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter in the prior year, the business posted ($1.05) EPS. Sell-side analysts expect that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, CFO Erick Lucera sold 2,362 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total transaction of $48,113.94. Following the sale, the chief financial officer directly owned 121,563 shares of the company’s stock, valued at $2,476,238.31. The trade was a 1.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Brian S. Posner acquired 2,000 shares of Dyne Therapeutics stock in a transaction on Monday, June 8th. The shares were bought at an average cost of $16.94 per share, for a total transaction of $33,880.00. Following the completion of the purchase, the director directly owned 24,500 shares of the company’s stock, valued at $415,030. The trade was a 8.89% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 9,000 shares of company stock valued at $156,800 and have sold 1,829,584 shares valued at $35,509,357. 9.46% of the stock is currently owned by corporate insiders.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.